Recipharm invests $750k in new GMP suite

By Melissa Fassbender

- Last updated on GMT

The suite during an MDI manufacturing process. (Image: Recipharm)
The suite during an MDI manufacturing process. (Image: Recipharm)

Related tags Research triangle park

Recipharm has opened a new GMP suite for clinical trial material manufacture at its North Carolina-based facility in Research Triangle Park.

The new suite enables the contract development and manufacturing organization (CDMO) to provide complete early development services at the Research Triangle Park location. These services include process development and scale-up, CTM manufacturing and packaging, product release and stability programs.

Ann Flodin, VP and General Manager at Recipharm Laboratories, explained the facility supports the manufacture of different non-sterile dosage forms, such as metered dose inhalers, semi-solids, and dry powder capsules.  

With this location being Recipharm’s center of excellence for orally inhaled and nasal drug products, and with an experienced research team in place, this is a natural development for the company, extending the capabilities of Recipharm group​,” Flodin told Outsourcing-Pharma.com.

The GMP suite is ISO 8 certified, features a walk-in downflow booth, and has the capacity to produce metered dose inhalers in up to 25L batches and offers semi-solid production capabilities up to 20L.

We see the inhalation and semi-solid industries growing, and needing additional clinical trial manufacturing support," ​Flodin added.

"Also, the location is central in Research Triangle Park which is a rapidly growing science and technology cluster, with easy access for visitors through the nearby RDU airport​.”

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars